• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.

作者信息

Li Yalun, Zhang Rui, Zhou Yongzhao, Song Juan, Luo Wenxin, Tian Panwen, Li Weimin

机构信息

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China.

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Sichuan, China; Lung Cancer Treatment Center, West China Hospital, Sichuan University, Sichuan, China.

出版信息

Clin Lung Cancer. 2019 May;20(3):e251-e255. doi: 10.1016/j.cllc.2018.12.004. Epub 2018 Dec 19.

DOI:10.1016/j.cllc.2018.12.004
PMID:30638795
Abstract
摘要

相似文献

1
Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review.吉非替尼耐药后，克唑替尼与吉非替尼联合用于伴有软脑膜转移且MET扩增的晚期肺腺癌：一例报告及文献综述
Clin Lung Cancer. 2019 May;20(3):e251-e255. doi: 10.1016/j.cllc.2018.12.004. Epub 2018 Dec 19.
2
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.肺腺癌患者对克唑替尼治疗有持久应答后获得 KRAS 突变和低水平 MET 扩增丢失。
Lung Cancer. 2019 Jul;133:20-22. doi: 10.1016/j.lungcan.2019.05.006. Epub 2019 May 6.
3
Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.厄洛替尼/克唑替尼联合治疗一名原发性EGFR突变加继发性MET扩增且获得新型克唑替尼耐药突变MET G1108C的肺腺癌患者。
Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324.
4
MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.MET Y1003S 点突变使肺腺癌患者对克唑替尼敏感。
Lung Cancer. 2019 Apr;130:84-86. doi: 10.1016/j.lungcan.2019.02.002. Epub 2019 Feb 4.
5
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.克唑替尼联合或不联合 EGFR-TKI 治疗 EGFR 突变型 NSCLC 患者 EGFR-TKI 治疗失败后获得性 MET 扩增：一项多中心回顾性研究。
J Transl Med. 2019 Feb 21;17(1):52. doi: 10.1186/s12967-019-1803-9.
6
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.在具有MET扩增的非小细胞肺癌细胞系中，将S-1添加到表皮生长因子受体抑制剂吉非替尼中可克服吉非替尼耐药性。
Clin Cancer Res. 2009 Feb 1;15(3):907-13. doi: 10.1158/1078-0432.CCR-08-2251.
7
Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.通过下一代测序在肺腺癌中鉴定出一种新型的对克唑替尼敏感的MET-ATXN7L1基因融合变体。
Ann Oncol. 2018 Dec 1;29(12):2392-2393. doi: 10.1093/annonc/mdy455.
8
Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.携带有 MET 扩增的 EGFR 突变型肺癌患者使用吉非替尼联合克唑替尼治疗获得成功。
Curr Probl Cancer. 2021 Oct;45(5):100702. doi: 10.1016/j.currproblcancer.2020.100702. Epub 2021 Jan 9.
9
Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.获得性MET-DSTN融合介导的肺腺癌对EGFR-TKIs耐药及对克唑替尼联合吉非替尼的反应：一例报告
Clin Lung Cancer. 2022 Jan;23(1):e83-e86. doi: 10.1016/j.cllc.2021.10.006. Epub 2021 Oct 25.
10
Mathematical analysis of gefitinib resistance of lung adenocarcinoma caused by MET amplification.MET 扩增导致肺腺癌对吉非替尼耐药的数学分析。
Biochem Biophys Res Commun. 2019 Apr 9;511(3):544-550. doi: 10.1016/j.bbrc.2019.02.086. Epub 2019 Feb 26.

引用本文的文献

1
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.大剂量奥希替尼用于表皮生长因子受体阳性非小细胞肺癌的中枢神经系统进展：一项多机构经验
JTO Clin Res Rep. 2022 Apr 21;3(6):100328. doi: 10.1016/j.jtocrr.2022.100328. eCollection 2022 Jun.
2
Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.克唑替尼与奥希替尼联合治疗T790M+表皮生长因子受体（EGFR）突变型非小细胞肺癌：一名10年生存者在奥希替尼进展后出现MET扩增的病例报告
Case Rep Oncol. 2021 Mar 18;14(1):477-482. doi: 10.1159/000513904. eCollection 2021 Jan-Apr.
3
Trifolium Flavonoids Overcome Gefitinib Resistance of Non-Small-Cell Lung Cancer Cell by Suppressing ERK and STAT3 Signaling Pathways.
三叶草类黄酮通过抑制 ERK 和 STAT3 信号通路克服非小细胞肺癌细胞对吉非替尼的耐药性。
Biomed Res Int. 2020 Oct 22;2020:2491304. doi: 10.1155/2020/2491304. eCollection 2020.
4
Long noncoding RNA HAS2-AS1 accelerates non-small cell lung cancer chemotherapy resistance by targeting LSD1/EphB3 pathway.长链非编码RNA HAS2-AS1通过靶向LSD1/EphB3通路加速非小细胞肺癌化疗耐药
Am J Transl Res. 2020 Mar 15;12(3):950-958. eCollection 2020.
5
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.表皮生长因子受体阳性非小细胞肺癌中共同驱动基因突变作为负预测因素。
EBioMedicine. 2019 Apr;42:304-310. doi: 10.1016/j.ebiom.2019.03.023. Epub 2019 Mar 14.